FI20030393A0 - Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi - Google Patents

Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Info

Publication number
FI20030393A0
FI20030393A0 FI20030393A FI20030393A FI20030393A0 FI 20030393 A0 FI20030393 A0 FI 20030393A0 FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A0 FI20030393 A0 FI 20030393A0
Authority
FI
Finland
Prior art keywords
forecasting
prevention
procedure
development
treatment
Prior art date
Application number
FI20030393A
Other languages
English (en)
Swedish (sv)
Other versions
FI20030393A (fi
Inventor
Pirkko Vihko
Veli Isomaa
Original Assignee
Molekyyliendokrinologian Tutki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molekyyliendokrinologian Tutki filed Critical Molekyyliendokrinologian Tutki
Priority to FI20030393A priority Critical patent/FI20030393A/fi
Publication of FI20030393A0 publication Critical patent/FI20030393A0/fi
Priority to PCT/FI2004/000145 priority patent/WO2004080271A2/en
Priority to EP04720024A priority patent/EP1603571A2/en
Publication of FI20030393A publication Critical patent/FI20030393A/fi
Priority to US11/225,095 priority patent/US20060057628A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
FI20030393A 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi FI20030393A (fi)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393A (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
PCT/FI2004/000145 WO2004080271A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
EP04720024A EP1603571A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
US11/225,095 US20060057628A1 (en) 2003-03-14 2005-09-14 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393A (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Publications (2)

Publication Number Publication Date
FI20030393A0 true FI20030393A0 (fi) 2003-03-14
FI20030393A FI20030393A (fi) 2004-09-15

Family

ID=8565817

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030393A FI20030393A (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Country Status (4)

Country Link
US (1) US20060057628A1 (fi)
EP (1) EP1603571A2 (fi)
FI (1) FI20030393A (fi)
WO (1) WO2004080271A2 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US8088758B2 (en) 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
MX2007007051A (es) * 2004-12-13 2007-06-26 Solvay Pharm Gmbh Nuevos derivados de tiofenpirimidiona sustituida como inhibidores de la 17??-hidroxiesteroide deshidrogenasa.
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
CN101884706B (zh) * 2010-07-01 2014-05-28 广州市花城制药厂 一种祛痰止咳颗粒的检测方法

Also Published As

Publication number Publication date
WO2004080271A3 (en) 2004-11-04
US20060057628A1 (en) 2006-03-16
FI20030393A (fi) 2004-09-15
EP1603571A2 (en) 2005-12-14
WO2004080271A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
SE0303226L (sv) Anordning och förfarande för tomografi
NO20044054L (no) Administrering av midler for behandling av betennelse
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
SE531352C8 (sv) Spiroalkanderivat och användning av dessa föreningar för behandling av artrit, cancer, kardiovaskulära sjukdomar, hudsjukdomar och inflammatoriska och allergiska tillstånd
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
FI20030393A (fi) Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
NO20063114L (no) Enoxaparin for behandling av cancer
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
SE0302718L (sv) Förfarande för utvinning av energi och kemilalier
FI20021112A0 (fi) Menetelmä ja järjestely paikannuksen suorittamiseksi
NO20014228L (no) Radioaktiv cisplatin i behandling av cancer
DE602004026067D1 (de) Gerät zur Behandlung von Füßen
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung
SE0300501L (sv) Användning och förfarande vid fotbollsskor
FI20022296A0 (fi) Paperin valmistuksessa käytettävä aine ja sen valmistus
AU2003247094A8 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors
NO20033160D0 (no) Anordning for behandling av gravann
FI20040325A (fi) Menetelmä ja järjestelmä biojätteen käsittelemiseksi
FI20040873A (fi) Koostumus pintojen käsittelyä varten ja sen käyttö

Legal Events

Date Code Title Description
FD Application lapsed